ATLANTA -- Chronic kidney disease patients in the landmark JUPITER trial achieved a 44% reduction in mortality if they were assigned to the potent cholesterol-lowering agent rosuvastatin (Crestor) when compared with patients who were on placebo, researchers said here.
